ClinicalTrials.gg
Sign In
CompletedNCT06802796Updated Jan 31, 2025

Plasma NGAL in APN Patients

An observational study in Pyelonephritis, sponsored by Kafrelsheikh University. Completed at 1 site in Egypt. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-01-31.

Sponsored by Kafrelsheikh University · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
120
Ages
20 Years and older
Sex
All
01

Study summary

In recent years, novel biomarkers of renal dysfunction have attracted attention for the diagnosis of UTIs. NGAL is a 25 kDa protein that belongs to the lipocalin. It acts as a transporter for small hydrophobic molecules and is involved in many physiological processes, such as modulating inflammation, innate immune response, and maintaining metabolic homeostasis

02

Conditions studied

  • Pyelonephritis

Browse trials for

03

In context

Pyelonephritis

79 studies on the registry are indexed under Pyelonephritis; 12 are open to participants now.

This study's enrollment of 120 is below the median of 153 across 15 observational studies indexed under Pyelonephritis.

Browse Pyelonephritis studies →

Lead sponsor

Kafrelsheikh University is the lead sponsor of 294 studies on the registry; 114 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Browse Kafrelsheikh University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All adult patient had fever due to renal infection

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • above 20 years Suspected have pyelonphirtis

Exclusion criteria

Exclusion Criteria:

  • age below 20
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
120 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Group A :patient with pyelonephritis

    patient with pyelonephritis

    Diagnostic Test: Plasma NGAL test

  • Group B :patient without pyelonephritis

    patient without pyelonephritis

    Diagnostic Test: Plasma NGAL test

Interventions

  • Diagnostic testPlasma NGAL test

    Human neutrophil gelatinase-associated lipocalin ELISA Kit from BT LAB® Bioassay technology laboratory was used for the estimation of serum NGAL. Procedure was done according to the manufacturer's instructions.

06

What researchers measure

Primary outcomes

  1. Result of plasma NGAL test

    Result of serum test of NGAL

    Time frame: One day

07

Study locations

1 site
  • Elsayed Abdelhalim Elsayed
    Zagazig, 44749, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Jun 2024, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2025
First posted
Jan 31, 2025
StartActual
Feb 1, 2024
Primary completionActual
Jun 1, 2024
CompletionActual
Jun 1, 2024
Last update
Jan 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06802796
Lead sponsor
Kafrelsheikh University
Responsible party
Elsayed Abdelhalim Elsayed (assistant lecturer of urology, Kafrelsheikh University) — Principal investigator
First posted
Jan 31, 2025
Start date
Feb 1, 2024
Primary completion
Jun 1, 2024
Completion
Jun 1, 2024
Last update
Jan 31, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Pyelonephritis →

Other studies from this sponsor

Kafrelsheikh University →

Start the discussion